Literature DB >> 21966238

Recommendations for the use of rotavirus vaccines in infants.

M Salvadori, N Le Saux.   

Abstract

Rotavirus infection occurs in the majority of healthy children before five years of age, and is the most common diarrheal illness associated with hospitalization. The majority of children present with symptoms of vomiting, diarrhea and fever. As a result, rotavirus gastroenteritis is responsible for greater morbidity than other common childhood diarrheal illnesses. The highest risk of severe disease is in children younger than two years of age. It is estimated that one in 20 children will require an emergency department visit. In addition to community-acquired infections, hospital-acquired infections are also significant. There are currently two licensed rotavirus vaccines in Canada. Both vaccines are administered orally and are highly effective against severe disease and hospitalization. Large pre- and postmarketing studies have shown no increased risk of intussusception with the current rotavirus vaccines. The present statement provides information concerning the clinical disease and rotavirus vaccines in Canada.

Entities:  

Keywords:  Acute gastroenteritis; Children; Diarrhea; Oral vaccine; Rotavirus; Vaccine

Year:  2010        PMID: 21966238      PMCID: PMC2952519          DOI: 10.1093/pch/15.8.519

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  30 in total

1.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.

Authors:  Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  Global Advisory Committee on Vaccine Safety, 6-7 June 2006.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2006-07-14

3.  More on RotaShield and intussusception: the role of age at the time of vaccination.

Authors:  L Simonsen; C Viboud; A Elixhauser; R J Taylor; A Z Kapikian
Journal:  J Infect Dis       Date:  2005-09-01       Impact factor: 5.226

4.  Hospitalization for community-acquired, rotavirus-associated diarrhea: a prospective, longitudinal, population-based study during the seasonal outbreak. The Greater Toronto Area/Peel Region PRESI Study Group. Pediatric Rotavirus Epidemiology Study for Immunization.

Authors:  E L Ford-Jones; E Wang; M Petric; P Corey; R Moineddin; M Fearon
Journal:  Arch Pediatr Adolesc Med       Date:  2000-06

5.  Substantial morbidity for hospitalized children with community-acquired rotavirus infections: 2005-2007 IMPACT surveillance in Canadian hospitals.

Authors:  Nicole Le Saux; Julie A Bettinger; Scott A Halperin; Wendy Vaudry; David W Scheifele
Journal:  Pediatr Infect Dis J       Date:  2010-09       Impact factor: 2.129

6.  Economic analysis of rotavirus-associated diarrhea in the metropolitan Toronto and Peel regions of Ontario.

Authors:  P Jacobs; Lg Shane; K Fassbender; El Wang; R Moineddin; El Ford-Jones
Journal:  Can J Infect Dis       Date:  2002-05

7.  Postmarketing monitoring of intussusception after RotaTeq vaccination--United States, February 1, 2006-February 15, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-03-16       Impact factor: 17.586

8.  Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.

Authors:  Penina Haber; Manish Patel; Hector S Izurieta; James Baggs; Paul Gargiullo; Eric Weintraub; Margaret Cortese; M Miles Braun; Edward A Belongia; Elaine Miller; Robert Ball; John Iskander; Umesh D Parashar
Journal:  Pediatrics       Date:  2008-06       Impact factor: 7.124

9.  Rotavirus infection in infants as protection against subsequent infections.

Authors:  F R Velázquez; D O Matson; J J Calva; L Guerrero; A L Morrow; S Carter-Campbell; R I Glass; M K Estes; L K Pickering; G M Ruiz-Palacios
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

10.  Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine.

Authors: 
Journal:  Pediatrics       Date:  2009-03-30       Impact factor: 7.124

View more
  6 in total

1.  Effectiveness of rotavirus vaccine in preventing severe acute gastroenteritis in children.

Authors:  Ran D Goldman
Journal:  Can Fam Physician       Date:  2012-03       Impact factor: 3.275

2.  Recommendations for the use of rotavirus vaccines in infants.

Authors:  Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2017-06-30       Impact factor: 2.253

3.  Rapid genotyping of human rotavirus using SYBR green real-time reverse transcription-polymerase chain reaction with melting curve analysis.

Authors:  Yupin Tong; Bonita E Lee; Xiaoli L Pang
Journal:  World J Virol       Date:  2015-11-12

4.  Rotavirus vaccination and short-term risk of adverse events in US infants.

Authors:  J Bradley Layton; Anne M Butler; Catherine A Panozzo; M Alan Brookhart
Journal:  Paediatr Perinat Epidemiol       Date:  2018-07-26       Impact factor: 3.980

5.  The impact of publicly funded rotavirus immunization programs on Canadian children.

Authors:  Pia K Muchaal; Matt Hurst; Shalini Desai
Journal:  Can Commun Dis Rep       Date:  2021-03-04

6.  Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals.

Authors:  Andrew McDermid; Nicole Le Saux; Elsie Grudeski; Julie A Bettinger; Kathy Manguiat; Scott A Halperin; Lily Macdonald; Pierre Déry; Joanne Embree; Wendy Vaudry; Timothy F Booth
Journal:  BMC Infect Dis       Date:  2012-11-15       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.